S
Rob Perez
EVP and COO, Cubist Pharmaceuticals
STARTED OUT: As a sales rep in South Central Los Angeles
WANTS TO: Ultimately be a high school basketball coach
A mere six months before Biogen's launch of Avonex, no sales plan had been written and only a skeleton crew had been put in place. But then Rob Perez and others came in and hammered out a commercial model for success.
Rob Perez
"I had a chance to design a sales model from scratch," says Perez, who came to run Biogen's US neurology franchise. "Avonex was wildly successful—with 50 percent share in seven months—because it was as great product, but also because the commercial model we put together worked well."
When Perez came to Cubist, he had the chance to do it all over again—and this time serve as the company's top commercial exec. The drug to be launched was Cubicin, an IV antibiotic that was effective in fighting MRSA and other bugs. But Perez and his team saw an opportunity to leverage the IV drug outside the hospital—and in so doing, made Cubicin the most successful IV antibiotic launch in US history.
Cubist saw that the ex-hospital approach was working, and upped the resources to capture the opportunity. Perez credits this quick thinking to the culture. "I've always worked at companies that have had to compete with the Pfizers of the world, who outspend you every time. So I try to find people who will ask, 'What can we do better tomorrow?' And if we do our job and put the right business processes in place so that we can learn from that faster, than we can gain a competitive advantage."
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.